GENMAB AS SP.ADR/1/10DK 1 Financial Flexibility Index
GENMAB AS SP.ADR/1/10DK 1 financial flexibility index. GENMAB AS SP.ADR/1/10DK 1 (GE91) has a Financial Flexibility Index of 0.04x as of December 2025. Free cash flow of €314.00 Million (operating CF €301.00 Million minus capex €13.00 Million) represents 0% of total liabilities (€7.03 Billion). See cash generation quality of GENMAB AS SP.ADR/1/10DK 1 to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of GENMAB AS SP.ADR/1/10DK 1 (2021–2025)
Financial flexibility index of GENMAB AS SP.ADR/1/10DK 1 from 2021 to 2025. Historical Financial Flexibility Index trend for GENMAB AS SP.ADR/1/10DK 1 across 5 annual periods. Check GENMAB AS SP.ADR/1/10DK 1 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
GENMAB AS SP.ADR/1/10DK 1 Financial Flexibility Index by Year (2021–2025)
GENMAB AS SP.ADR/1/10DK 1 financial flexibility index by year from 2021 to 2025. Year-by-year free cash flow to debt coverage for GENMAB AS SP.ADR/1/10DK 1. For the full cash flow conversion analysis, see GE91 cash flow conversion.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.18x | €1.24 Billion | €1.19 Billion | €7.03 Billion | ▼ -80.1% |
| 2024 | 0.89x | €1.13 Billion | €1.08 Billion | €1.27 Billion | ▼ -58.0% |
| 2023 | 2.11x | €1.15 Billion | €1.10 Billion | €546.23 Million | ▲ +41.4% |
| 2022 | 1.49x | €608.67 Million | €563.05 Million | €408.32 Million | ▲ +46.1% |
| 2021 | 1.02x | €377.55 Million | €339.18 Million | €370.09 Million | — |